The Bcl-2 related protein Bad is a promoter of apoptosis and has been shown to dimerize with the anti-apoptotic proteins Bcl-2 and Bcl-x L . Overexpression of Bad in murine FL5.12 cells demonstrated that the protein not only could abrogate the protective capacity of coexpressed Bcl-x L but could accelerate the apoptotic response to a death signal when it was expressed in the absence of exogenous Bcl-x L . Using deletion analysis, we have identified the minimal domain in the murine Bad protein that can dimerize with Bcl-x L . A 26-aminoacid peptide within this domain, which showed significant homology to the alpha-helical BH3 domains of related apoptotic proteins like Bak and Bax, was found to be necessary and sufficient to bind Bcl-x L . To determine the role of dimerization in regulating the death-promoting activity of Bad and the death-inhibiting activity of Bcl-x L , mutations within the hydrophobic BH3-binding pocket in Bcl-x L that eliminated the ability of Bcl-x L to form a heterodimer with Bad were tested for the ability to promote cell survival in the presence of Bad. Several of these mutants retained the ability to impart protection against cell death regardless of the level of coexpressed Bad protein. These results suggest that BH3-containing proteins like Bad promote cell death by binding to antiapoptotic members of the Bcl-2 family and thus inhibiting their survival promoting functions.
Apoptosis or programmed cell death is a highly conserved and essential feature of development and homeostasis in higher organisms. Environmental or developmental cues trigger intracellular signaling pathways that can culminate in either a death or survival response from the cell. A study of the molecular events underlying these intracellular signaling pathways has, in recent years, resulted in the identification of a large number of molecules that are involved either in promoting or in suppressing the apoptotic response.
One such group of genes, the Bcl-2 family, comprises both promoters and inhibitors of death. Among the inhibitors are Bcl-2 (17, 31) , Bcl-x L (1), Bcl-w (11), Mcl-1 (20) , adenovirus E1B 19K (12, 25, 34) , Epstein-Barr virus BHRF1 (14) , and Caenorhabditis elegans Ced-9 (15, 16) . Death agonists include Bax (24) , Bak (8, 19) , Bad (35) , Bik (3, 13) , Bid (33) , and Bcl-x S (1, 21) . The original classification of this family of genes was based on the presence of two conserved domains which were designated Bcl-2 homology domains BH1 and BH2 (36) . More recently, two additional domains, BH3 and, to some extent, BH4, have also been recognized as important in delineating the Bcl-2-related genes (3, 7, 23, 29, 30, 32) . While all four homology regions are present in some proteins such as Bcl-2 and Bcl-x L , many other Bcl-2 proteins lack one or more of these domains. Bak and Bax are BH1, BH2, and BH3 proteins (7, 38) , while Bik and Bid contain only the BH3 region (13, 33) . Bad has been classified as a BH1-BH2-containing protein based on homology alignments (35) . Most BH1-BH2-containing proteins in the Bcl-2 family harbor carboxy-terminal signal anchor sequences and are predominantly localized to the mitochondrial membrane and nuclear envelope (1, 17) . In contrast, Bad lacks a signal anchor sequence (35) .
An important feature of the Bcl-2 family is that its members are capable of dimerizing with themselves or with other members of the family. These protein-protein interactions constitute an important regulatory mechanism because the ratio between pro-and antiapoptotic dimers may, in some cases, be the primary factor determining the response of a cell to a death signal (1, 8, 10, 24, 35) . The antiapoptotic abilities of Bcl-2 and Bcl-x L have been reported to correlate with their ability to form heterodimers with Bax (28, 36) .
A three-dimensional structural analysis of the Bcl-x L protein revealed that, in monomeric form, it consists of two central hydrophobic helices surrounded by amphipathic helices (23) . A hydrophobic pocket, which is created by the spatial proximity of the BH1, BH2, and BH3 domains, provides a binding site for the death-promoting proteins (23, 26) . The death-promoting proteins interact with this binding site through their BH3 domains. Thus, for death suppressors such as Bcl-2 and Bcl-x L , it is the BH1, BH2, and BH3 sequences that contribute to the interaction with death agonists such as Bax and Bak (6, 23, 26, 28, 35, 36) . In contrast, for death agonists, it is the BH3 region alone that is important for apoptotic activity and in heterodimerization with the death inhibitors (7, 13, 33, 38) .
In addition, some Bcl-2-related proteins are subject to additional levels of regulation. Using the interleukin-3 (IL-3)-dependent murine pro-B-cell line FL5.12, Zha and coworkers showed that in the presence of IL-3, Bad is hyperphosphorylated and is unable to associate with Bcl-x L . Instead, it remains sequestered by the cytosolic phosphoserine-binding protein 14-3-3 (39) . However, following IL-3 deprivation, Bad undergoes rapid dephosphorylation and in this form is able to dimerize with Bcl-x L . Although the sites of phosphorylation on Bad have been mapped (39) , the region on the protein involved in dimerization with Bcl-x L has yet to be defined. In this study, we show that Bad, like other death agonists, interacts with Bcl-x L through a region of the protein resembling a BH3 domain. We also show that the ability of Bad to induce cell death is dependent on its ability to dimerize with antiapoptotic members of the Bcl-2 family.
MATERIALS AND METHODS
Cell lines, plasmid constructs, and transfections. The FL5.12 murine pro-Bcell line was cultured as previously described (1) . The Bad gene was initially cloned from a murine splenic library and subcloned into the EcoRI site of pBluescript II SK ϩ (Stratagene). Deletion mutants of Bad were generated by PCR with oligonucleotides to create translation initiation codons preceded by EcoRI cloning sites for the 5Ј deletions and stop codons followed by EcoRI cloning sites for the 3Ј deletions. Internal deletions were generated by two-step recombinant PCR (9) . Inserts were cloned into pBluescript II SK ϩ and confirmed by sequencing. The valine 126 and tyrosine 101 point mutants of Bcl-x L were generated by using the Chameleon site-directed mutagenesis kit (Stratagene). Bcl-x L point mutants and full-length Bad were subcloned into the expression vector pSFFV-Neo (1) for the transfection experiments. Ten micrograms of pSFFV-Neo, pSFFV-Bcl-x L (1), or pSFFV-Bad was used for single plasmid transfections, and 5 g each of pSFFV-Bcl-x L (or pSFFV-valine 126 mutants) and pSFFV-Bad was used for the cotransfections. Ten million FL5.12 cells were electroporated at 960 F and 250 V. Neomycin-resistant cells were selected in medium containing 1 mg of G418 per ml. Single-cell clones were obtained from transfectant pools by limiting dilution cloning in 96-well microtiter plates.
Cell viability assays. The viability of the IL-3-dependent FL5.12 cell line was assayed over a period of 4 days following withdrawal of IL-3 from the medium. The cells were washed three times in growth medium lacking IL-3 and resuspended in this medium at a concentration of 5 ϫ 10 5 cells/ml. Aliquots were withdrawn at specific time intervals, and their viability was determined by propidium iodide exclusion and fluorescence-activated cell sorter (FACS) analysis (2, 37) .
Western blot analyses. Cells were pelleted, washed in phosphate-buffered saline, and then lysed in radioimmunoprecipitation buffer containing 1% Nonidet P-40, 1% deoxycholate, and 0.1% sodium dodecyl sulfate (SDS), and supplemented with 8 g of aprotinin, 2 g of leupeptin, and 170 g of phenylmethylsulfonyl fluoride per ml. The lysed cells were centrifuged at 14,000 ϫ g to remove cellular debris. Protein concentrations of extracts were determined by the colorimetric bicinchoninic acid analysis (Pierce Chemical Company). Equal amounts of protein were electrophoretically separated in SDS-15% polyacrylamide gels and transferred to nitrocellulose (Amersham). Membrane blocking, washing, primary and secondary antibody incubations, and chemiluminescence reactions were carried out according to the Amersham ECL protocol. Blots were stripped for reuse by washing for 30 min to 2 h in TBS-T buffer (pH 3.0) at room temperature. The monoclonal antibody 2A1 was used to detect Bcl-x L (21) , and the polyclonal rabbit antibody C-20 (Santa Cruz) was used to detect Bad.
Detection of protein-protein interactions in vitro and in vivo.
Bcl-x L , Bad, Bax, and mutants in pBluescript were translated in vitro with the TNT T7 Quick Coupled Transcription/Translation System (Promega) for T7 transcripts and the TNT T7/T3 Coupled Reticulocyte Lysate System (Promega) for T3 transcripts. Translated products were labeled by including 20 Ci of [
35 S]methionine per 50 l of reaction mixture. Equal amounts of labeled, in vitro-translated products were combined together in NET-N buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris [pH 8.0], 0.2% Nonidet P-40) supplemented with 8 g of aprotinin, 2 g of leupeptin, and 170 g of PMSF per ml, and incubated overnight at 4°C, with gentle agitation. The binding reactions were processed as described in Minn et al. (21) , with the following variations: Bad-Bcl-x L interactions were immunoprecipitated with the Bad polyclonal antibody 10929 (35) and Bax-Bcl-x L interactions were immunoprecipitated with an anti-human Bax polyclonal antiserum (Pharmingen). For in vivo coimmunoprecipitations, 10 7 FL5.12 cells, which were incubated in IL-3-free medium for 6 h, were lysed in 500 l of NET-N buffer supplemented with protease inhibitors, and the lysates were cleared of debris by centrifugation at 14,000 ϫ g. Supernatants were precleared and processed as described by Chang et al. (4) , with the following variations: anti-Bcl-x L monoclonal antibody 7B2 (21) was used to immunoprecipitate Bad-Bcl-x L complexes, and coimmunoprecipitated Bad was detected by Western blotting with anti-Bad antibody C-20 and the Amersham ECL protocol. An equal amount of precleared lysate was also subjected to electrophoresis and Western blotting for the detection of total Bad protein in each extract.
In vitro fluorescence titrations. The affinities of peptide binding to full-length Bcl-x L were measured by fluorescence titrations. Recombinant Bcl-x L was prepared as described elsewhere (23), and the peptides were purchased from PeptidoGenic Research & Co. (Livermore, Calif.) and purified by reverse-phase high-performance liquid chromatography on a C8 column. For the titration, the fluorescence emission of the Trp residues of Bcl-x L was monitored as a function of increasing peptide concentration. The fluorescence measurements were done on a Shimadzu RF5000U spectrofluorometer with excitation and emission wavelengths of 290 and 340 nm, respectively. The Trp fluorescence intensity was fit by using the equation ⌬I obs ϭ X b ϫ ⌬I (b Ϫ f) , where ⌬I obs is the difference between the observed intensity and the fluorescence intensity of the free protein, X b is the mole fraction of the bound state, and ⌬I (b Ϫ f) is the fluorescence difference between the bound and free forms of the protein. Mole fractions were calculated from a dissociation constant, K D , by using the known initial concentrations of the protein and peptide. A least-squares analysis was then performed by systematic variation of K D and ⌬I (b Ϫ f) . A linear correction for peptide fluorescence was applied to the Bad 26-mer prior to data analysis.
RESULTS
Bad can both abrogate the protective capacity of coexpressed Bcl-x L in FL5.12 cells and accelerate the apoptotic response following IL-3 deprivation. The molecular mechanism by which Bcl-2-related proteins promote cell death remains controversial. Bad has been shown to be a potent inducer of cell death in Bcl-x L -expressing cells. Bad has also been shown to dimerize with the death inhibitor Bcl-x L (35, 39) . However, it is not known whether Bad is a death inducer whose function is inhibited upon dimerization with Bcl-x L or whether Bcl-x L , as a death inhibitor, is the primary effector rendered inactive upon dimerization with Bad. As an initial test of the ability of Bad to induce cell death directly, FL5.12 cells were transfected with either Bad alone or Bad and Bcl-x L plasmids together. Three clones from the cotransfection and the Bad VOL. 17, 1997 Bad IS A BH3 PROTEIN 7041
on January 18, 2018 by guest http://mcb.asm.org/ bulk transfectants were tested for their viability over 4 days following IL-3 deprivation (Fig. 1A ). An FL5-Bcl-x L subclone expressing high levels of transfected Bcl-x L protein (22) was used as a positive control, and a neomycin-resistant clone (Neo) was used as a transfection control. Clones BB1.01 and BB1.06 express both Bad and Bcl-x L at high levels (Fig. 1B) . However, overexpressed Bad is able to abrogate the protective influence of Bcl-x L (also shown previously [35] ). Equivalent amounts of Bcl-x L expressed in the absence of Bad are sufficient to impart prolonged survival in the absence of IL-3, as in the case of the FL5-Bcl-x L clone (see Fig. 4B ) (22) . BB2.12, a clone expressing near background levels of transfected Bcl-x L and only moderate levels of Bad, died more rapidly than the Neo transfectants. The Bad bulk transfectants also exhibited an accelerated response to IL-3 withdrawal, with only 10% of the population remaining viable at 24 h compared to the Neo controls, which remained 50% viable at 24 h. These data demonstrate that the proapoptotic effect of Bad supersedes the survival-promoting function of Bcl-x L . Since FL5.12 cells express low levels of endogenous Bcl-2 and Bcl-x L , Bad may accelerate death by inhibiting the function of the endogenous survival genes in these assays. Alternatively, Bad may promote cell death independently of dimerization with endogenous Bcl-2 or Bcl-x L .
Bad dimerizes with Bcl-x L through a BH3 domain. To define the role of dimerization in the proapoptotic function of Bad, we examined the structural requirements for the interaction of Bad with Bcl-x L . A series of deletion mutants of Bad were constructed and tested for their abilities to bind Bcl-x L in vitro ( Fig. 2A, B, and C) . The shortest deletion mutant that could be recognized by the immunoprecipitating anti-Bad polyclonal antibody and still interact with Bcl-x L was 104-182. Interestingly, alignment of the 79-amino-acid region 104-182 of Bad with Bcl-2-related proteins revealed a predicted alpha-helical region with significant similarity to other BH3 alpha-helices ( Fig. 3A and B) . Deletion of residues 145 to 160 resulted in complete loss of binding, while the deletion of another predicted alpha-helical stretch between amino acids 115 and 129 retained the ability to dimerize with Bcl-x L ( Fig. 2 and 3A) . Similar results were obtained with an anti-Bcl-x L monoclonal antibody to immunoprecipitate the bound complexes (not shown). These results suggested the presence of a BH3-like domain in Bad that is important in mediating the interaction with Bcl-x L .
A 26-residue peptide encompassing the BH3 domain of Bad exhibits high-level binding affinity and displaces full-length Bad and Bax from Bcl-x L heterodimers. To test whether the 16-residue BH3 homology region, which was deleted in plasmid ⌬145-160 (Fig. 2) , was sufficient to bind the hydrophobic binding pocket of Bcl-x L , a 16-residue peptide was synthesized and assayed for its ability to compete with full-length Bad or Bax for interaction with Bcl-x L . Surprisingly, the peptide failed to compete with either full-length protein (not shown). Fluorescence titrations to measure the binding affinity of this peptide to Bcl-x L revealed very low-level binding affinity in comparison with 16-mer Bak and Bax BH3 peptides (Table 1) . Although the coimmunoprecipitations (Fig. 2B) indicated that deletion of amino acids 145 to 160 in Bad was sufficient to abrogate binding, it is possible that residues outside this 16-residue span are required for anchoring the BH3 region of Bad to the binding pocket in Bcl-x L . The predicted alpha-helical domain in this region of Bad is flanked by proline residues at positions 139 and 166 (Fig. 3A) . Since proline residues present in primary amino acid sequences often serve structurally to terminate helical domains, a larger peptide encompassing the 26 amino acids between these two prolines was synthesized and tested for its ability to bind Bcl-x L . Fluorescence titrations with the Bad (140-165) peptide showed a binding affinity more than 30-fold higher than that of a 23-residue Bak (72-94) peptide (Table 1) . When it was used as a competitor of Bad or Bax association with Bcl-x L in vitro ( Fig. 4A and B) , this Bad BH3 peptide was able to prevent both Bad and Bax from dimerizing with Bcl-x L . Furthermore, 50-to 100-fold more Bad peptide was required to inhibit the interaction of Bcl-x L with Bad compared to Bax, suggesting that Bad associates more strongly with Bcl-x L . A 16-mer Bak BH3 peptide, which was previously shown to bind within the hydrophobic pocket of Bcl-x L (26), was also able to displace Bad from Bcl-x L -Bad heterodimers (Fig. 4A) . The Bcl-x L BH3 peptide, which had previously been shown to be a poor competitor of Bax binding (26) , was unable to displace Bad even at a concentration of 200 M. These data support the deletion analysis (Fig. 2) in confirming the presence of a BH3 domain in Bad that is involved in dimerization with Bcl-x L .
Bad is unable to promote death in the absence of dimerization. Based on the residues involved in the binding of Bcl-x L to BH3 domains, which were identified by the nuclear magnetic resonance (NMR) structure of the Bcl-x L -Bak peptide complex, a series of mutants that alter the ligand binding properties of the Bcl-x L BH1/BH2/BH3 pocket (23) were created. These Bcl-x L mutants were tested for their ability to associate with full-length Bad in vitro. Mutants of the Bcl-x L hydrophobic pocket that lost survival-promoting properties also lost the ability to bind Bad, and, for the most part, mutants of Bcl-x L that retained death-inhibiting properties also retained the ability to dimerize with Bad (not shown). However, a tyrosine 101-to-lysine (Y101K) mutant that imparts partial protection to FL5.12 cells in viability assays (not shown) did not associate with Bad (Fig. 5) , which suggested that Bcl-x L and not Bad might be the primary effector of function.
The above hypothesis was confirmed by the development of another set of mutations involving valine at position 126 of Bcl-x L . The three-dimensional structure of a Bcl-x L -Bak peptide complex (26) has shown that valine 126 contributes to a deep hydrophobic pocket which accommodates leucine 78 of the Bak protein. This leucine is conserved in all BH3-containing proteins identified to date (Fig. 3B) . Mutations of Bcl-x L in which valine 126 was converted to either glycine, alanine, or glutamic acid were created. All three mutants, V126A, V126E, and V126G, were able to impart full protection to IL-3-deprived FL5.12 cells in viability assays (Fig. 6 and data not shown). However, only the alanine mutant dimerized with Bad in vitro (Fig. 6A) . Bax did not dimerize with either the alanine or the glycine mutant and dimerized only very weakly with the glutamate mutant in this assay (Fig. 6A) . V126A-and V126G-expressing constructs were then cotransfected with Bad into FL5.12 cells. From each transfection, three individual clones expressing comparable levels of Bcl-x L but different amounts of the Bad protein (Fig. 6B) were selected for further study. Figure 6C shows the results of viability assays performed on these cell lines. Both wild-type Bcl-x L -Bad cell lines and V126A-Bad cell lines displayed profiles suggesting that increasing levels of Bad roughly correlate with a diminished ability of Bcl-x L to inhibit apoptosis. However, the three V126G-expressing clones displayed similar resistance to apoptosis, irrespective of the levels of expressed Bad protein.
Transfectants expressing the highest levels of Bad in each transfection category (Fig. 6A, top panel) were used in coprecipitation studies. Immunoprecipitation of Bcl-x L from lysates of IL-3-deprived cells followed by Western blotting with an antibody against Bad confirmed the lack of association between Bcl-x L V126G and Bad observed in vitro (Fig. 6D, bottom panel) . Western blots confirmed that the levels of Bad expressed by the three cell lines were comparable (Fig. 6D, top  panel) . Anti-Bcl-x L Western blots demonstrated that comparable amounts of Bcl-x L were brought down by the immunoprecipitation (data not shown). These results suggest that Bad exerts its death-promoting influence primarily by dimerizing with Bcl-x L and inactivating the protein.
DISCUSSION
Protein-protein interactions between the proapoptotic and antiapoptotic members of the Bcl-2 family of proteins play an important role in the regulation of programmed cell death. It is known that these interactions exhibit a hierarchy (27, 28) and that, in general, this binding selectivity is conferred upon death-promoting members by their BH3 domains (26) . An issue still at large, however, is whether these death-promoting members function as primary effectors of apoptotic death or whether they act to promote death by inactivating the survival functions of the death agonists. Our results strongly suggest that the death effector Bad acts by dimerizing with antiapoptotic proteins such as Bcl-x L and thus inactivating or modulating their survival functions.
The BH3 domain in all proapoptotic proteins of the family appears to be critical for their interaction with death suppressors. In the case of Bak, which possesses BH1, BH2, and BH3 domains, small truncated forms of the protein containing the BH3 domain were sufficient both for killing cells and for binding to Bcl-x L (7). Additionally, insertion of the BH3 domain of Bax in Bcl-2 converts Bcl-2 into a death agonist (18) . In the present study, we have shown that Bad, a death promoter, harbors a BH3 domain that is involved in heterodimerization with Bcl-x L . Based on our characterization, the weak homologies within Bad to BH1 and BH2 domains are not likely to be significant, since the BH3 domain defined in our study partially overlaps BH1 and lies between the previously postulated BH1 and BH2 domains (Fig. 3A) . In all Bcl-2-related proteins with recognized BH1, BH2, and BH3 domains, the BH3 domain precedes BH1 and BH2 in the primary amino acid sequence, an order that is required for appropriate alpha-helical packing as deduced from the three-dimensional structure of Bcl-x L (23) . Our studies also indicate that Bad binds Bcl-x L more strongly than either Bax or Bak.
It has previously been shown that transfected Bad inhibited the ability of coexpressed death suppressors such as Bcl-x L and Bcl-2 to protect cells (35) . We have confirmed these observations. Our results further suggest that the inhibition is dependent on the level of Bad expression. In addition, Bad protein expressed in the absence of exogenous Bcl-x L causes an acceleration of the apoptotic response in FL5.12 cells. One explanation for this may be that overexpressed Bad dimerizes with the endogenous Bcl-2 and Bcl-x L in the cells or with other not yet discovered death inhibitors of the Bcl-2 family and blocks any residual protection afforded by the endogenous protein(s). The inability of high levels of Bad to counteract the protective ability of the Bcl-x L valine-to-glycine mutant at residue 126, with which it cannot heterodimerize, supports this explanation. A recent study showing that the antiapoptotic function of E1B 19K, which can dimerize with Bax but not with Bad, could not be counteracted by overexpression of Bad (5) also suggests that Bad is unable to exert a proapoptotic effect in the absence of dimerization. However, Bad cannot promote apoptosis simply by displacing Bax from Bcl-x L heterodimers, since Bcl-x L V126A, which, like wild-type Bcl-x L , is unable to protect cells in the presence of high levels of Bad, fails to bind Bax, although one cannot rule out the possibility that Bad may be displacing other Bax-like death promoters that were still able to heterodimerize with the V126A mutant.
Coprecipitation experiments in vitro indicated that deletion of a 16-residue sequence exhibiting the best homology to a BH3 consensus was sufficient to abrogate dimerization of Bad with Bcl-x L . Although a synthetic 16-residue peptide of the same sequence showed poor binding affinity in two different assays, a 26-mer encompassing this region of Bad bound tightly to Bcl-x L . The large difference in binding affinities between the 16-mer (145-160) and 26-mer (140-165) Bad peptides suggests that additional amino acids present in the 26-mer may be involved in the Bcl-x L -Bad complex. Determination of the specific residues involved in dimerization, however, can come only from a resolution of the structure of the Bcl-x L -Bad 26-mer complex accompanied by point mutational analysis of this region. Coprecipitation experiments in vitro also indicate that, like other death agonists (26) , Bad probably interacts with residues in the hydrophobic pocket of Bcl-x L . This is demonstrated by the ability of the Bad and Bak BH3 peptides to block the dimerization of Bad with Bcl-x L .
Bad appears to be a member of a rapidly growing list of BH3-only proteins (13, 33) . As more such proteins emerge, it is becoming clear that the BH3 domain, in promoting apoptosis, acts by functional sequestration of antiapoptotic activity rather than as an independently functioning effector domain. The importance of the BH3 region is further underscored by the existence of proteins such as Bad, Bid, and Bik which show no similarity beyond this highly conserved domain. The necessity for this redundancy, i.e., for a cell to require multiple BH3-containing regulatory proteins, suggests that the existence of a network of independently regulated pathways within a cell that may be selected in response to different stimuli. The Bad protein, for example, is phosphorylated in the presence of IL-3 in the FL5.12 cell line and is rapidly dephosphorylated upon withdrawal of the cytokine (39) . In addition, the death promoter Bid can bind to either the antiapoptotic protein Bcl-x L or the proapoptotic protein Bax (33) , suggesting that it may also have a regulated ability either to promote cell death or to potentiate cell viability.
